SEC Info  
    Home      Search      My Interests      Help      Sign In      Please Sign In

Evolent Health, Inc. – ‘10-K’ for 12/31/19 – ‘R14’

On:  Monday, 3/2/20, at 6:11am ET   ·   For:  12/31/19   ·   Accession #:  1628908-20-32   ·   File #:  1-37415

Previous ‘10-K’:  ‘10-K’ on 2/28/19 for 12/31/18   ·   Next:  ‘10-K’ on 2/26/21 for 12/31/20   ·   Latest:  ‘10-K’ on 2/23/24 for 12/31/23   ·   2 References:   

Find Words in Filings emoji
 
  in    Show  and   Hints

  As Of               Filer                 Filing    For·On·As Docs:Size

 3/02/20  Evolent Health, Inc.              10-K       12/31/19  150:20M

Annual Report   —   Form 10-K   —   Sect. 13 / 15(d) – SEA’34
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 10-K        Annual Report                                       HTML   2.78M 
 2: EX-4.8      Instrument Defining the Rights of Security Holders  HTML     64K 
 3: EX-21.1     Subsidiaries List                                   HTML     42K 
 4: EX-23.1     Consent of Experts or Counsel                       HTML     40K 
 5: EX-23.2     Consent of Experts or Counsel                       HTML     40K 
 6: EX-31.1     Certification -- §302 - SOA'02                      HTML     48K 
 7: EX-31.2     Certification -- §302 - SOA'02                      HTML     48K 
 8: EX-32.1     Certification -- §906 - SOA'02                      HTML     42K 
 9: EX-32.2     Certification -- §906 - SOA'02                      HTML     42K 
133: R1          Cover Page                                          HTML    105K  
79: R2          Consolidated Balance Sheets                         HTML    162K 
30: R3          Consolidated Balance Sheets (Parenthetical)         HTML     52K 
112: R4          Consolidated Statements of Operations and           HTML    138K  
                Comprehensive Income (Loss)                                      
134: R5          Consolidated Statements of Changes in               HTML    144K  
                Shareholders' Equity (Deficit)                                   
80: R6          Consolidated Statements of Cash Flows               HTML    166K 
31: R7          Organization                                        HTML     48K 
115: R8          Basis of Presentation, Summary of Significant       HTML    149K  
                Accounting Policies and Change in Accounting                     
                Principle                                                        
132: R9          Recently Issued Accounting Standards                HTML     51K  
136: R10         Transactions                                        HTML    155K  
84: R11         Revenue Recognition                                 HTML     94K 
38: R12         Property and Equipment, Net                         HTML     58K 
55: R13         Goodwill and Intangible Assets, Net                 HTML    127K 
137: R14         Long-term Debt                                      HTML     97K  
85: R15         Commitments and Contingencies                       HTML    108K 
39: R16         Leases                                              HTML     80K 
56: R17         Earnings (Loss) Per Common Share                    HTML     76K 
135: R18         Stock-based Compensation                            HTML    186K  
86: R19         Income Taxes                                        HTML    202K 
28: R20         Employee Benefit Plans                              HTML     43K 
82: R21         Investments In and Advances to Equity Method        HTML     97K 
                Investees                                                        
130: R22         Non-controlling Interests                           HTML     73K  
113: R23         Fair Value Measurement                              HTML    168K  
29: R24         Related Parties                                     HTML     76K 
83: R25         Segment Reporting                                   HTML    173K 
131: R26         Reserves for Claims and performance-Based           HTML     98K  
                Arrangements                                                     
114: R27         Investments                                         HTML    105K  
33: R28         Quarterly Results of Operations (Unaudited)         HTML     93K 
81: R29         Supplemental Cash Flow Information                  HTML     83K 
53: R30         Basis of Presentation, Summary of Significant       HTML    245K 
                Accounting Policies and Change in Accounting                     
                Principle (Policies)                                             
37: R31         Basis of Presentation, Summary of Significant       HTML    140K 
                Accounting Policies and Change in Accounting                     
                Principle (Tables)                                               
88: R32         Transactions (Tables)                               HTML     90K 
139: R33         Revenue Recognition (Tables)                        HTML     74K  
52: R34         Property and Equipment, Net (Tables)                HTML     58K 
36: R35         Goodwill and Intangible Assets, Net (Tables)        HTML    120K 
87: R36         Long-term Debt (Tables)                             HTML     58K 
138: R37         Commitments and Contingencies (Tables)              HTML     78K  
54: R38         Leases (Tables)                                     HTML     75K 
34: R39         Earnings (Loss) Per Common Share (Tables)           HTML     79K 
75: R40         Stock-based Compensation (Tables)                   HTML    167K 
27: R41         Income Taxes (Tables)                               HTML    192K 
100: R42         Investments In and Advances to Equity Method        HTML     90K  
                Investees Investments In and Advances to Equity                  
                Method Investees (Tables)                                        
120: R43         Non-controlling Interests (Tables)                  HTML     55K  
73: R44         Fair Value Measurement (Tables)                     HTML    219K 
25: R45         Related Parties (Tables)                            HTML     71K 
99: R46         Segment Reporting (Tables)                          HTML    170K 
118: R47         Reserves for Claims and performance-Based           HTML     91K  
                Arrangements (Tables)                                            
76: R48         Investments (Tables)                                HTML    106K 
22: R49         Quarterly Results of Operations (Unaudited)         HTML     93K 
                (Tables)                                                         
46: R50         Supplemental Cash Flow Information (Tables)         HTML     82K 
65: R51         Organization (Details)                              HTML     45K 
140: R52         Basis of Presentation, Summary of Significant       HTML     41K  
                Accounting Policies and Change in Accounting                     
                Principle - Operating Segments (Details)                         
91: R53         Basis of Presentation, Summary of Significant       HTML     89K 
                Accounting Policies and Change in Accounting                     
                Principle - Restricted Cash and Restricted                       
                Investments (Details)                                            
48: R54         Basis of Presentation, Summary of Significant       HTML     57K 
                Accounting Policies and Change in Accounting                     
                Principle - Notes Receivable (Details)                           
66: R55         Basis of Presentation, Summary of Significant       HTML     52K 
                Accounting Policies and Change in Accounting                     
                Principle - Estimated Useful Life of Property,                   
                Plant and Equipment (Details)                                    
141: R56         Basis of Presentation, Summary of Significant       HTML     44K  
                Accounting Policies and Change in Accounting                     
                Principle - Research and Development Costs                       
                (Details)                                                        
92: R57         Basis of Presentation, Summary of Significant       HTML     42K 
                Accounting Policies and Change in Accounting                     
                Principle - Goodwill (Details)                                   
50: R58         Basis of Presentation, Summary of Significant       HTML     53K 
                Accounting Policies and Change in Accounting                     
                Principle - Intangible Assets, Net (Details)                     
62: R59         Basis of Presentation, Summary of Significant       HTML     43K 
                Accounting Policies and Change in Accounting                     
                Principle - Impairment of Equity Method                          
                Investments (Details)                                            
126: R60         Basis of Presentation, Summary of Significant       HTML     45K  
                Accounting Policies and Change in Accounting                     
                Principle - Revenue Recognition (Details)                        
104: R61         Basis of Presentation, Summary of Significant       HTML     45K  
                Accounting Policies and Change in Accounting                     
                Principle - Stock-based Compensation (Details)                   
18: R62         Recently Issued Accounting Standards (Details)      HTML     47K 
67: R63         Transactions - Passport (Details)                   HTML     71K 
129: R64         Transactions - New Century Health (Details)         HTML    144K  
107: R65         Transactions - New Mexico Health Connections        HTML     83K  
                (Details)                                                        
21: R66         Transactions - Pro Forma Information (Unaudited)    HTML     55K 
                (Details)                                                        
70: R67         Transactions - Securities Offerings and Sales       HTML    143K 
                (Details)                                                        
122: R68         Transactions - Asset Acquisitions (Details)         HTML     53K  
109: R69         Revenue Recognition - Disaggregation of Revenue     HTML     59K  
                (Details)                                                        
98: R70         Revenue Recognition - Transaction Price Allocated   HTML     45K 
                to the Remaining Performance Obligations (Details)               
147: R71         Revenue Recognition - Contract Balances (Details)   HTML     80K  
60: R72         Revenue Recognition - Contract Costs (Details)      HTML     52K 
44: R73         Property and Equipment, Net (Details)               HTML     68K 
95: R74         Goodwill and Intangible Assets, Net - Impairment    HTML     59K 
                Testing (Details)                                                
144: R75         Goodwill and Intangible Assets, Net - Schedule of   HTML     63K  
                Goodwill (Details)                                               
57: R76         Goodwill and Intangible Assets, Net - Intangible    HTML     71K 
                Assets, Net (Details)                                            
41: R77         Goodwill and Intangible Assets, Net - Amortization  HTML     57K 
                of Intangible Assets (Details)                                   
94: R78         Long-term Debt - Credit Agreement (Details)         HTML     84K 
149: R79         Long-term Debt - Warrant Agreement (Details)        HTML     47K  
97: R80         Long-term Debt - 2025 Notes (Details)               HTML     92K 
146: R81         Long-term Debt - 2021 Notes (Details)               HTML     78K  
59: R82         Long-term Debt - Convertible Senior Notes Carrying  HTML     73K 
                Value (Details)                                                  
43: R83         Commitments and Contingencies - Additional          HTML     95K 
                Information (Details)                                            
96: R84         Commitments and Contingencies - Purchase            HTML     49K 
                Obligations (Details)                                            
145: R85         Commitments and Contingencies - Reinsurance         HTML     54K  
                Agreements (Details)                                             
58: R86         Commitments and Contingencies - Concentration Risk  HTML     65K 
                (Details)                                                        
42: R87         Leases - Narratives (Details)                       HTML     51K 
93: R88         Leases - Material Office Leases (Details)           HTML     63K 
148: R89         Leases - Components of Lease Expense (Details)      HTML     52K  
127: R90         Leases - Maturity of Lease Liabilities (Details)    HTML     62K  
105: R91         Leases - Weighted-average Discount Rate and         HTML     44K  
                Weighted-remaining Lease Terms (Details)                         
19: R92         Earnings (Loss) Per Common Share - Computation of   HTML     74K 
                Earnings per Share (Details)                                     
68: R93         Earnings (Loss) Per Common Share - Antidilutive     HTML     54K 
                Securities (Details)                                             
128: R94         Stock-based Compensation - 2011 and 2015 Equity     HTML     64K  
                Incentive Plans (Details)                                        
106: R95         Stock-based Compensation - Stock-based              HTML     63K  
                Compensation Expense (Details)                                   
20: R96         Stock-based Compensation - Unrecognized             HTML     59K 
                Compensation Expense (Details)                                   
69: R97         Stock-based Compensation - Stock Options (Details)  HTML     74K 
124: R98         Stock-based Compensation - Stock Option Activity    HTML     95K  
                (Details)                                                        
111: R99         Stock-based Compensation - Performance-based Stock  HTML    115K  
                Option Awards (Details)                                          
23: R100        Stock-based Compensation - Restricted Stock Units   HTML     85K 
                (Details)                                                        
77: R101        Stock-based Compensation - Leveraged Stock Units    HTML     75K 
                (Details)                                                        
116: R102        Stock-based Compensation - Leveraged Stock Units    HTML     62K  
                Activity (Details)                                               
101: R103        Stock-based Compensation - Performance-based RSUs   HTML     65K  
                (Details)                                                        
24: R104        Income Taxes - Narrative (Details)                  HTML     95K 
78: R105        Income Taxes - Schedule of Loss Before Provision    HTML     48K 
                for Income Taxes (Details)                                       
117: R106        Income Taxes - Income Tax Expense (Benefit)         HTML     75K  
                (Details)                                                        
102: R107        Income Taxes - Reconciliation of Statutory Rate to  HTML     86K  
                Effective Tax Rate (Details)                                     
26: R108        Income Taxes - Deferred Tax Assets and Liabilities  HTML    105K 
                (Details)                                                        
74: R109        Income Taxes - Changes in Valuation Allowance       HTML     51K 
                (Details)                                                        
63: R110        Income Taxes - Changes In Unrecognized Tax          HTML     56K 
                Benefits (Details)                                               
51: R111        Employee Benefit Plans (Details)                    HTML     42K 
90: R112        Investments In and Advances to Equity Method        HTML     87K 
                Investees (Details)                                              
143: R113        Investments In and Advances to Equity Method        HTML     75K  
                Investees - Schedule of Assets and Liabilities and               
                Maximum Loss Exposure of Unconsolidated VIEs                     
                (Details)                                                        
61: R114        Investments In and Advances to Affiliates -         HTML     77K 
                Summarized Financial Information (Details)                       
49: R115        Non-controlling Interests (Details)                 HTML    155K 
89: R116        Fair Value Measurement - Assets and Liabilities on  HTML     84K 
                Recurring Basis (Details)                                        
142: R117        Fair Value Measurement (Details)                    HTML     50K  
64: R118        Fair Value Measurement - Changes in Contingent      HTML     51K 
                Consideration and Other (Details)                                
45: R119        Fair Value Measurement - Valuation Techniques and   HTML    100K 
                Significant Unobservable Inputs (Details)                        
110: R120        Related Parties (Details)                           HTML     45K  
123: R121        Related Parties - Assets and Liabilities (Details)  HTML     68K  
72: R122        Related Parties - Revenues and Expenses (Details)   HTML     68K 
17: R123        Segment Reporting (Details)                         HTML    109K 
108: R124        Segment Reporting - Reconciliation of Adjusted      HTML     98K  
                EBITDA (Details)                                                 
121: R125        Reserves for Claims and performance-Based           HTML     70K  
                Arrangements - Claims Reserves (Details)                         
71: R126        Investments - Investment Summary (Details)          HTML     63K 
15: R127        Investments - Contractual Maturity (Details)        HTML     66K 
103: R128        Investments - Unrealized Losses (Details)           HTML     49K  
125: R129        Quarterly Results of Operations (Unaudited)         HTML     68K  
                (Details)                                                        
150: R130        Supplemental Cash Flow Information (Details)        HTML     94K  
47: R9999       Uncategorized Items - evh12311910-k.htm             HTML     42K 
40: XML         IDEA XML File -- Filing Summary                      XML    285K 
32: XML         XBRL Instance -- evh12311910-k_htm                   XML   5.24M 
119: EXCEL       IDEA Workbook of Financial Reports                  XLSX    198K  
11: EX-101.CAL  XBRL Calculations -- evh-20191231_cal                XML    432K 
12: EX-101.DEF  XBRL Definitions -- evh-20191231_def                 XML   1.64M 
13: EX-101.LAB  XBRL Labels -- evh-20191231_lab                      XML   3.24M 
14: EX-101.PRE  XBRL Presentations -- evh-20191231_pre               XML   2.23M 
10: EX-101.SCH  XBRL Schema -- evh-20191231                          XSD    330K 
16: JSON        XBRL Instance as JSON Data -- MetaLinks              667±  1.06M 
35: ZIP         XBRL Zipped Folder -- 0001628908-20-000032-xbrl      Zip    748K 


‘R14’   —   Long-term Debt


This is an IDEA Financial Report.  [ Alternative Formats ]



 
v3.19.3.a.u2
Long-term Debt
12 Months Ended
Debt Disclosure [Abstract]  
Long-term Debt Long-term Debt

Credit Agreement

On December 30, 2019, the Company entered into a credit agreement, by and among the Company, the Borrower, certain subsidiaries of the Company, as guarantors, the lenders from time to time party thereto, and Ares Capital Corporation, as administrative agent and collateral agent, together with the Company, pursuant to which the lenders agreed to extend credit to the Borrower in the form of (i) an initial secured term loan in the aggregate principal amount of $75.0 million (the “Initial Term Loan Facility”) and (ii) a delayed draw secured term loan facility in the aggregate principal amount of up to $50.0 million (the “DDTL Facility” and, together with the Initial Term Loan Facility, the “Senior Credit Facilities”), subject to the satisfaction of specified conditions. The Borrower borrowed the loan under the Initial Term Loan Facility on December 30, 2019. In connection with the Credit Agreement, on December 30, 2019, the Company entered into a Security Agreement, by and among the Company, the Borrower, the other guarantors and the collateral agent for the benefit of the secured parties, and a Guarantee Agreement, by the Company and each of the other guarantors in favor of the collateral agent for the benefit of the secured parties. The Senior Credit Facilities are guaranteed by the Company and the Company’s domestic subsidiaries, subject to certain exceptions. The Senior Credit Facilities are secured by a first priority security interest in all of the capital stock of the borrower and each guarantor (other than the Company) and substantially all of the assets of the borrower and each guarantor, subject to certain exceptions.
The proceeds of the Initial Term Loan was used to finance the Passport transaction, fees and expenses incurred in connection therewith. The proceeds of the DDTL Facility may be used, subject to our satisfaction of specified conditions, to finance the repayment or repurchase of the Company’s 2.00% Convertible Senior Notes due December 1, 2021 and to fund permitted acquisitions.  The Initial Term Loan and any loans under the DDTL Facility will mature on the date that is the earliest of (a) December 30, 2024, (b) the date on which all amounts outstanding under the Credit Agreement have been declared or have automatically become due and payable under the terms of the Credit Agreement and (c) the date that is ninety-one (91) days prior to the maturity date of the 2021 Convertible Notes unless certain liquidity conditions are satisfied (the foregoing, the “Maturity Date”). The interest rate for each loan under the Senior Credit Facilities is calculated, at the option of the Borrower, at either the eurodollar rate plus 8.00%, or the base rate plus 7.00%. A commitment fee of 1.00% per annum is payable by the Borrower quarterly in arrears on the unused portion of the DDTL Facility.
Amounts outstanding under the Senior Credit Facilities may be prepaid at the option of the Borrower subject to applicable premiums, including a make-whole premium payable on certain prepayments made prior to the second anniversary of the closing of the Senior Credit Facilities, and a call protection premium payable on the amount prepaid in certain instances as follows: (1) 4.00% of the principal amount so prepaid after the second anniversary of the closing of the Senior Credit Facilities but prior the third anniversary of the closing of the Senior Credit Facilities; (2) 3.00% of the principal amount so prepaid after the third anniversary of the closing of the Senior Credit Facilities but prior the fourth anniversary of the closing of the Senior Credit Facilities; and (3)2.00% of the principal amount so prepaid after the fourth anniversary of the closing of the Senior Credit Facilities but prior the fifth anniversary of the closing of the Senior Credit Facilities. Amounts outstanding under the Senior Credit Facility are subject to mandatory prepayment upon the occurrence of certain events and conditions, including non-ordinary course asset dispositions, receipt of certain casualty proceeds, issuances of certain debt obligations and a change of control transaction.
The Senior Credit Facilities contain customary borrowing conditions, affirmative, negative and reporting covenants, representations and warranties, and events of default, including cross-defaults to other material indebtedness. In addition, the Company is required to comply at certain times with certain financial covenants comprised of a minimum net revenue test and a minimum liquidity test commencing
upon closing of the Senior Credit Facilities and a total secured leverage ratio commencing on the last day of the fiscal quarter ending March 31, 2021. If an event of default occurs, the lenders would be entitled to take enforcement action, including foreclosure on collateral and acceleration of amounts owed under the Senior Credit Facilities. We incurred $4.7 million of debt issuance costs in connection with this credit agreement, which will be included in long-term debt, net of discount on our consolidated balance sheets and will be amortized into interest expense over the life of the agreement. The Company was in compliance with all required covenants as of December 31, 2019.
Warrant Agreement
In conjunction with the Company’s entry into the credit agreement, the Company entered into warrant agreements whereby it agreed to sell to the holders of the warrants an aggregate of 1,513,786 shares of Class A common stock at a per share purchase price equal to $8.05. The holders can exercise the warrants at any time until thirty days after the maturity of the credit agreement. The Company, at its sole discretion, can elect to pay the holders in cash in an amount determined based on the fair market value of the Class A common stock for the shares of Class A common stock issuable upon exercise of the warrants in lieu of delivering the shares.
2025 Notes

In October 2018, the Company issued $172.5 million aggregate principal amount of its 1.50% Convertible Senior Notes due 2025 in a private placement to qualified institutional buyers within the meaning of Rule 144A under the Securities Act of 1933, as amended. The 2025 Notes were issued at par for net proceeds of $166.6 million. We incurred $5.9 million of debt issuance costs in connection with the 2025 Notes. The closing of the private placement of $150.0 million aggregate principal amount of the 2025 Notes occurred on October 22, 2018, and the Company completed the offering and sale of an additional $22.5 million aggregate principal amount of the 2025 Notes on October 24, 2018, pursuant to the initial purchasers’ exercise in full of their option to purchase additional notes.

Holders of the 2025 Notes are entitled to cash interest payments, which are payable semiannually in arrears on April 15 and October 15 of each year, beginning on April 15, 2019, at a rate equal to 1.50% per annum. The Company recorded interest expense of $2.6 million and $0.5 million related to the 2025 Notes for the years ended December 31, 2019 and 2018. The 2025 Notes will mature on October 15, 2025, unless earlier repurchased, redeemed or converted in accordance with their terms prior to such date.

Prior to the close of business on the business day immediately preceding April 15, 2025, the 2025 Notes will be convertible at the option of the holders only upon the satisfaction of certain conditions, as described in the indenture, dated as of October 22, 2018, between the Company and U.S. Bank National Association, as trustee. At any time on or after April 15, 2025, until the close of business on the business day immediately preceding the maturity date, holders may convert, at their option, all or any portion of their notes at the conversion rate.

The 2025 Notes will be convertible at an initial conversion rate of 29.9135 shares of Class A common stock per $1,000 principal amount of notes, which is equivalent to an initial conversion price of approximately $33.43 per share of the Company’s Class A common stock. In the aggregate, the 2025 Notes are initially convertible into 5.2 million shares of the Company’s Class A common stock (excluding any shares issuable by the Company upon a conversion in connection with a make-whole fundamental change or a notice of redemption as described in the governing indenture). The conversion rate may be adjusted under certain circumstances. The 2025 Notes are convertible, in multiples of $1,000 principal amount, at the option of the holders at any time prior to the close of business on the business day immediately preceding the maturity date. Upon conversion, the Company will pay or deliver, as the case may be, cash or shares of the Company’s Class A common stock, or a combination of cash and shares of the Company’s Class A common stock, at the Company’s election.

The option to settle the 2025 Notes in cash or shares of the Company’s Class A common stock, or a combination of cash and shares of the Company’s Class A common stock, at the Company’s election, resulted in a bifurcation of the carrying value of the 2025 Notes into a debt component and an equity component. The debt component was determined to be $100.7 million, before issuance costs, based on the fair value of a nonconvertible debt instrument with the same term. The equity component was determined to be $71.8 million, before issuance costs, and was recorded within additional paid-in capital. The equity component is the difference between the aggregate principal amount of the debt and the debt component. Issuance costs of $3.4 million and $2.5 million are allocated to the debt and equity components in proportion to the allocation of proceeds. Along with the equity component of $71.8 million, $3.4 million of issuance costs will be amortized to interest expense on the consolidated statements of operations and comprehensive income (loss). using the effective interest method over the contractual term of the 2025 Notes. The equity component recorded within additional paid-in capital will not be remeasured as long as it meets the conditions for equity classification. For the years ended December 31, 2019 and 2018, the Company recorded $8.5 million and $1.5 million, respectively, in interest expense related to the amortization of the debt discount and the issuance costs allocated to the debt component.

Holders of the 2025 Notes may require the Company to repurchase all or part of their notes upon the occurrence of a fundamental change at a price equal to 100.0% of the principal amount of the notes being repurchased, plus any accrued and unpaid interest to, but excluding, the fundamental change repurchase date. The Company may not redeem the 2025 Notes prior to October 20, 2022. The Company may redeem for cash all or any portion of the 2025 Notes, at its option, on or after October 20, 2022, if the last reported sale price of the Company’s Class A common stock has been at least 130.0% of the conversion price then in effect for at least 20 trading days (whether or not consecutive) during any 30 consecutive trading day period (including the last trading day of such period) ending on, and including,
the trading day immediately preceding the date on which the Company provides notice of redemption, at a redemption price equal to 100.0% of the principal amount of the notes to be redeemed, plus accrued and unpaid interest to, but excluding, the redemption date.

2021 Notes

In December 2016, the Company issued $125.0 million aggregate principal amount of its 2.00% Convertible Senior Notes due 2021 in a private placement to qualified institutional buyers within the meaning of Rule 144A under the Securities Act of 1933, as amended. The 2021 Notes were issued at par for net proceeds of $120.4 million. We incurred $4.6 million of debt issuance costs in connection with the 2021 Notes, which we are amortizing to non-cash interest expense using the straight-line method over the contractual term of the 2021 Notes, since this method was not materially different from the effective interest method. The closing of the private placement of the 2021 Notes occurred on December 5, 2016.

Holders of the 2021 Notes are entitled to cash interest payments, which are payable semiannually in arrears on June 1 and December 1 of each year, beginning on June 1, 2017, at a rate equal to 2.00% per annum. The 2021 Notes will mature on December 1, 2021, unless earlier repurchased or converted in accordance with their terms prior to such date. In addition, holders of the 2021 Notes may require the Company to repurchase their 2021 Notes upon the occurrence of a fundamental change at a price equal to 100.00% of the principal amount of the 2021 Notes being repurchased, plus any accrued and unpaid interest. Upon maturity, and at the option of the holders of the 2021 Notes, the principal amount of the notes may be settled via shares of the Company’s Class A common stock. We recorded interest expense of $2.5 million and non-cash interest expense related to the amortization of deferred financing costs of $0.9 million for each of the years ended December 31, 2019, 2018 and 2017, respectively.

The 2021 Notes are convertible into shares of the Company’s Class A common stock, based on an initial conversion rate of 41.6082 shares of Class A common stock per $1,000 principal amount of the 2021 Notes, which is equivalent to an initial conversion price of approximately $24.03 per share of the Company’s Class A common stock. In the aggregate, the 2021 Notes are initially convertible into 5.2 million shares of the Company’s Class A common stock (excluding any shares issuable by the Company upon a conversion in connection with a make-whole provision upon a fundamental change under the governing indenture. The conversion rate may be adjusted under certain circumstances).

The 2021 Notes are convertible, in multiples of $1,000 principal amount, at the option of the holders at any time prior to the close of business on the business day immediately preceding the maturity date. Upon conversion, we will deliver for each $1,000 principal amount of notes converted a number of shares of our Class A common stock equal to the applicable conversion rate (together with a cash payment in lieu of delivering any fractional share) on the third business day following the relevant conversion date.

Convertible Senior Notes Carrying Value

The 2025 Notes and 2021 Notes are recorded on our accompanying consolidated balance sheets at their net carrying values of $107.2 million and $123.2 million, respectively, as of December 31, 2019. However, the 2025 Notes and 2021 Notes are privately traded by qualified institutional buyers (within the meaning of Rule 144A under the Securities Act of 1933, as amended) and their fair values were $122.0 million and $111.3 million, respectively, based on traded prices on December 31, 2019 and December 11, 2019, respectively, which are Level 2 inputs. As of December 31, 2018, the estimated fair value of the 2025 and 2021 Notes were $158.8 million and $133.6 million, respectively, based on a traded price on December 28, 2018 and December 26, 2018, respectively, which are Level 2 inputs. The 2025 Notes and the 2021 Notes also have embedded conversion options and contingent interest provisions, which have not been recorded as separate financial instruments.

The following table summarizes the carrying value of the long-term convertible debt (in thousands):
 
 
2019
 
2018
2025 Notes
 
 
 
Carrying value
$
107,169

 
$
98,730

Unamortized debt discount and issuance costs allocated to debt
65,331

 
73,770

Principal amount
$
172,500

 
$
172,500

Remaining amortization period (years)
5.8

 
6.8

 
 
 
 
2021 Notes
 
 
 
Carrying value
$
123,237

 
$
122,311

Unamortized issuance costs
1,763

 
2,689

Principal amount
$
125,000

 
$
125,000

Remaining amortization period (years)
1.9

 
2.9



Dates Referenced Herein   and   Documents Incorporated by Reference

This ‘10-K’ Filing    Date    Other Filings
10/15/25
4/15/25
12/30/24
10/20/22
12/1/21
3/31/21
Filed on:3/2/204
For Period end:12/31/198-K
12/30/198-K,  8-K/A
12/11/19
4/15/19
12/31/1810-K
12/28/18
12/26/18
10/24/188-K
10/22/188-K
6/1/174
12/5/168-K
 List all Filings 


2 Subsequent Filings that Reference this Filing

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 6/15/21  Evolent Health, Inc.              S-8         6/15/21    4:87K
 2/26/21  Evolent Health, Inc.              10-K       12/31/20  152:19M
Top
Filing Submission 0001628908-20-000032   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
AboutPrivacyRedactionsHelp — Wed., May 15, 1:35:26.1am ET